Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer

EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the Company’s proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs.

Dr. Richardson has over 25 years of research and development experience in the pharmaceutical and medical device industry. He has created centers of excellence that have enabled and supported product development pipelines encompassing small molecules, biologics, novel formulations, combination products, and medical devices. During his career, Dr. Richardson has managed clinical development programs leading to the submission, review, and approvals of NDAs, sNDAs, BLAs and Marketing Authorization Applications in the U.S., Europe and Japan for over 20 marketed products.

Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “Peter brings a wealth of experience and expertise in multiple therapeutic areas including endocrinology and product development to the organization. As we remain focused on advancing our proprietary pipeline with ATRS-1901, a urology-oncology auto-injector product, and ATRS-1902, an endocrinology rescue pen, we believe his career in the pharmaceutical industry and proven track record, will support our continued success and further enhance the opportunities around our portfolio and technology. We are pleased to welcome Peter to the leadership team as we prepare for our next stage of growth.”

From 2016 until the acquisition of the company in 2020, Dr. Richardson was Chief Medical Officer for Adare Pharmaceuticals and Vice President of Research and Development and President, Adare Pharmaceuticals US. From 2012 to 2016, he served as Head of Clinical and Regulatory Affairs and Chief Medical Officer at Alcon, the eye care division of Novartis, having previously led development organizations for Novartis Pharmaceuticals from 1996 to 2005, where he was responsible for successful product approvals in multiple therapeutic areas. He also previously served as Chief Scientific Officer and Corporate Vice President of MannKind Corporation from 2005 to 2012.